ECASS III and SITS-ISTR results confirm the conclusions of the analysis of the pooled data from randomized trials of tPA for ischemic stroke [5]: IV alteplase administered between 3 to 4.5 hours after symptoms onset is effective and, despite a higher risk of symptomatic intracranial haemorrhage as compared to placebo, this treatment is as safe as given within the approved 3-hour window. The gene discussed is PLAT; the disease is intracranial hemorrhage.